Penchi Biogroup

Penchi Biogroup is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of long-acting injectable (LAI) formulations. The company utilizes its proprietary Penchi-Sphere microsphere technology platform to create sustained-release versions of established therapeutics, primarily targeting the central nervous system, metabolic disorders, and endocrine diseases. Their lead programs include long-acting formulations of risperidone for schizophrenia and octreotide for acromegaly, designed to improve patient compliance and therapeutic outcomes. By focusing on high-barrier drug delivery systems, Penchi Biogroup aims to address significant unmet needs in chronic disease management. The company is supported by prominent venture capital firms and operates out of the Suzhou Industrial Park.